Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Sickle Cell Disease
In brief
A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
Key facts
- Study ID
- NCT05519111
- Run by
- Icahn School of Medicine at Mount Sinai
- People needed
- 60
- Starts
- 2025-04-03
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2025-10-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mount Sinai Hospital — New York, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.